絞り込み

16555

広告

日欧で低負担実現 初の大規模協力 (毎日新聞)

日本と欧州が協力して水星を調査する「ベピ・コロンボ計画」の探査機2機が19日(日本時間20日)、南米・仏領ギアナのクールー宇宙基地から欧州のアリアン5ロケットで...

  1. 変わり果てた「山水画」の世界に、中国の開...
  2. 石炭火力、保険引き受け停止相次ぐ - 日...
  3. 1-617【ミドル記事】★外国語(トルコ...
  4. 「人種差別に遺伝学使うな」米学会、白人至...

ニュース一覧

Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.

著者 Sugano K
Therap Adv Gastroenterol.2018 ; 11():1756283X17745776.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (413view , 0users)

Full Text Sources

Potassium-competitive acid blocker (P-CAB) is a class of drug that competitively blocks the potassium-binding site of H+, K+-adenosine triphosphate (ATP)ase. Although the history of this class of drugs started over 30 years ago, clinical use of two P-CABs, revaprazan and vonoprazan, were only recently approved in Korea and Japan, respectively. Among them, vonoprazan has several advantages over conventional proton-pump inhibitors (PPIs), including rapid onset of action, long duration of acid suppression, fewer interindividual variations in terms of acid suppression, and minimum dietary influence on its action. These advantages of vonoprazan have been proved in clinical trials conducted for license approvals for several acid-related diseases. In this review article, current evidence of vonoprazan in the management of gastroesophageal reflux disease (GERD) will be summarized. Since the clinical trial data, as well as postmarketed clinical data, have consistently demonstrated superiority of vonoprazan over conventional PPIs in terms of achieving healing of mucosal breaks and maintaining the healing, it may provide an excellent, if not complete, option for fulfilling some of the unmet needs for current GERD therapy. The safety problem of vonoprazan is also discussed, as more pronounced hypergastrinemia inevitably ensues with its use.
PMID: 29383028 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード